TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:19
Biohaven Ltd. ( BHVN ) https://www.biohavenpharma.com
36.42USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-15.85%
BHVN
SPY
32.66%
-73.50%
BHVN
SPY
108.59%
-35.00%
BHVN
SPY
302.52%
BHVN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3373.80
3023.98
0.67
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.19
6.63
10.68
-12.29
0.00
-3.49
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
14.072
-269.99
-169.66
2.65
Other Earnings and Cash Flow Stats:
Biohaven Ltd. ( BHVN ) Net Income TTM ($MM) is -804.34
Biohaven Ltd. ( BHVN ) Operating Income TTM ($MM) is -848.89
Biohaven Ltd. ( BHVN ) Owners' Earnings Annual ($MM) is 0.00
Biohaven Ltd. ( BHVN ) Current Price to Owners' Earnings ratio is 0.00
Biohaven Ltd. ( BHVN ) EBITDA TTM ($MM) is -841.60
Biohaven Ltd. ( BHVN ) EBITDA Margin is 0.00%
Capital Allocation:
Biohaven Ltd. ( BHVN ) has paid 0.00 dividends per share and bought back -26.052034 million shares in the past 12 months
Biohaven Ltd. ( BHVN ) has reduced its debt by 2.579 million USD in the last 12 months
Capital Structure:
Biohaven Ltd. ( BHVN ) Interest-bearing Debt ($MM) as of last quarter is 28
Biohaven Ltd. ( BHVN ) Annual Working Capital Investments ($MM) are -117
Biohaven Ltd. ( BHVN ) Book Value ($MM) as of last quarter is 316
Biohaven Ltd. ( BHVN ) Debt/Capital as of last quarter is 9%
Other Balance Sheet Stats:
Biohaven Ltd. ( BHVN ) has 84 million in cash on hand as of last quarter
Biohaven Ltd. ( BHVN ) has 152 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Biohaven Ltd. ( BHVN ) has 94 common shares outstanding as of last quarter
Biohaven Ltd. ( BHVN ) has 0 million USD of preferred stock value
Academic Scores:
Biohaven Ltd. ( BHVN ) Altman Z-Score is 2.26 as of last quarter
Biohaven Ltd. ( BHVN ) Piotroski Score is 1.00 as of last quarter
Corporate Governance:
Biohaven Ltd. ( BHVN ) largest shareholder is owning shares at 0.00 ($MM) value
CHILDS JOHN W(an insider) Bought 21052 shares of Biohaven Ltd. ( BHVN ) for the amount of $999970.00 on 2024-10-02
11.16% of Biohaven Ltd. ( BHVN ) is held by insiders, and 87.30% is held by institutions
Biohaven Ltd. ( BHVN ) went public on 2022-09-23
Other Biohaven Ltd. ( BHVN ) financial metrics:
FCF:-531.06
Unlevered Free Cash Flow:0.00
EPS:-6.79
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-202.91
Beta:2.65
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Biohaven Ltd. ( BHVN ) :
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.